• news.cision.com/
  • Swedish Orphan Biovitrum AB/
  • The board of directors of Swedish Orphan Biovitrum AB (publ) utilizes authorization to repurchase shares to secure the company's performance based, long-term share programs
English

The board of directors of Swedish Orphan Biovitrum AB (publ) utilizes authorization to repurchase shares to secure the company's performance based, long-term share programs

Report this content 

                        
The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) resolved on 27
April 2010 to issue not more than 1,552,949 series C shares to ensure that the
company can fulfill its commitments under the performance based, long-term share
programs 2008, 2009 and 2010 (the "Share Programs"). Furthermore, the Annual
General Meeting resolved to authorize the board of directors to repurchase all
issued series C shares for a price per share corresponding to the quota value of
the company's share, i.e. in total approximately SEK 852,098. The series C
shares will thereafter be converted to common shares in the number that is
required to ensure delivery under the Share Programs.

The board of directors of the company has resolved to utilize the authorization
for to repurchase all issued series C shares in accordance with the resolution
by the Annual General Meeting on 27 April 2010.

The company currently holds 515,585 own series C shares.

About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical
company with an international market presence. The company is focused on
providing and developing specialist pharmaceuticals for rare disease patients
with high medical needs. The portfolio consists of about 60 marketed products
and an emerging late stage clinical development pipe-line. Our focus areas are:
hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer and
inherited metabolic disorders. Swedish Orphan Biovitrum had pro-forma revenues
2009e of about 2 BSEK and approximately 500 employees. The head office is
located in Sweden and the share (STO: SOBI) is listed on NASDAQ OMX Stockholm.
For more information please visitwww.sobi.com.

For more information please contact:
Erik Kinnman, Vice President Investor Relations
Phone: +46 73 422 15 40
E-mail:erik.kinnman@sobi.com

Swedish Orphan Biovitrum may be required to disclose the information provided
herein pursuant to the Swedish Securities Markets Act and/or the Financial
Instruments Trading Act. The information was provided for public release on
December 23, 2010 at 12:00 p.m. (CET).







                                            

                

            

        

    

    



    

        
 Subscribe

        

            

        

    


        

            
        

        

            
        

        



    

        
 Documents & Links